semaglutide who makes it Turns out all those studies

When administered as a once-daily subcutaneous injection, Saxenda acts on several mechanisms to promote weight loss: Appetite suppression : It acts on areas of the brain that regulate appetite, helping patients feel fuller for longer periods Delayed gastric emptying : The medication slows the rate at which food leaves the stomach, contributing to prolonged satiety Improved glucose regulation : It enhances insulin secretion when blood glucose levels are elevated According to the Summary of Product Characteristics (SmPC), Saxenda is licensed for adults with a body mass index (BMI) of 30 kg/m or greater, or 27 kg/m or greater in the presence of weight-related comorbidities such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea

It works peripherally by slowing down gastric emptying (keeping food in your stomach longer) and centrally by activating receptors in the hypothalamus to shut down food noise and obsessive thoughts about eating

Renal physiol

Retatrutide is currently in Phase 3 clinical trials, which means it successfully passed Phase 1 (safety in healthy volunteers) and Phase 2 (efficacy and safety in target population)

It took the FDA until 2004 to warn about this worrisome complication

Most weight loss experts recommend 0.7 to 1.0 grams of protein per pound of goal body weight daily while on GLP-1 medications